Literature DB >> 8383007

A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas.

J Tsutsui1, K Kadomatsu, S Matsubara, A Nakagawara, M Hamanoue, S Takao, H Shimazu, Y Ohi, T Muramatsu.   

Abstract

Midkine (MK) and heparin-binding growth-associated molecule/pleiotrophin form a new family of heparin-binding growth/differentiation factors. We studied MK gene expression in human tumors. In normal human reference tissues, MK was highly expressed in the mucosal tissue of the small intestine, moderately in the thyroid, weakly in the tissues of the lung, colon, stomach, kidney, and spleen, and not at all in the liver. All of 6 surgically removed specimens of Wilms' tumor highly expressed MK. Also, a moderate to intense level of MK expression was noted in the majority of surgically removed hepatocellular carcinomas. The MK mRNA level was analyzed in a number of cultured and nude mice-transplanted lines of human tumors. In stomach, colon, pancreatic, lung, and esophageal carcinomas, a moderate to high level of MK expression was found in the majority of them. These results suggest an important role of MK in the development and/or biological behavior of tumors and raised a possibility to use MK as a diagnostic marker. Heparin-binding growth associated molecule/pleiotrophin mRNA was low or scarcely detectable in samples analyzed thus far except for significant levels of the expression that were observed in PA-1 teratocarcinoma cells and in some surgical specimens of Wilms' tumor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383007

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Nuclear targeting by the growth factor midkine.

Authors:  Yoshihisa Shibata; Takashi Muramatsu; Makoto Hirai; Tatsuya Inui; Terutoshi Kimura; Hidehiko Saito; Lynn M McCormick; Guojun Bu; Kenji Kadomatsu
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

2.  Midkine and pleiotrophin have bactericidal properties: preserved antibacterial activity in a family of heparin-binding growth factors during evolution.

Authors:  Sara L Svensson; Mukesh Pasupuleti; Björn Walse; Martin Malmsten; Matthias Mörgelin; Camilla Sjögren; Anders I Olin; Mattias Collin; Artur Schmidtchen; Ruth Palmer; Arne Egesten
Journal:  J Biol Chem       Date:  2010-03-22       Impact factor: 5.157

Review 3.  Structure and function of midkine as the basis of its pharmacological effects.

Authors:  T Muramatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

4.  Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta.

Authors:  K Meng; A Rodriguez-Peña; T Dimitrov; W Chen; M Yamin; M Noda; T F Deuel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

5.  Promotion of self-renewal of embryonic stem cells by midkine.

Authors:  Xing Yao; Zhou Tan; Bin Gu; Rong-rong Wu; Yu-kan Liu; Li-cheng Dai; Ming Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-05       Impact factor: 6.150

6.  Recombinant human midkine stimulates proliferation of articular chondrocytes.

Authors:  Z H Zhang; H X Li; Y P Qi; L J Du; S Y Zhu; M Y Wu; H L Lu; Y Yu; W Han
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

Review 7.  Involvement of midkine in neuroblastoma tumourigenesis.

Authors:  S Kishida; K Kadomatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

8.  PKCδ/midkine pathway drives hypoxia-induced proliferation and differentiation of human lung epithelial cells.

Authors:  Hanying Zhang; Miyako Okamoto; Evgeniy Panzhinskiy; W Michael Zawada; Mita Das
Journal:  Am J Physiol Cell Physiol       Date:  2014-02-05       Impact factor: 4.249

Review 9.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

10.  Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.

Authors:  M Takagi-Kimura; T Yamano; M Tagawa; S Kubo
Journal:  Cancer Gene Ther       Date:  2014-02-28       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.